Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Détails

ID Serval
serval:BIB_6B3D3B8E5C16
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Périodique
Neurobiology of aging
Auteur(s)
Cerami C., Dubois B., Boccardi M., Monsch A.U., Demonet J.F., Cappa S.F.
Collaborateur(s)
Geneva Task Force for the Roadmap of Alzheimer's Biomarkers
ISSN
1558-1497 (Electronic)
ISSN-L
0197-4580
Statut éditorial
Publié
Date de publication
04/2017
Peer-reviewed
Oui
Volume
52
Pages
153-166
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Although Alzheimer's disease criteria promote the use of biomarkers, their maturity in clinical routine still needs to be assessed. In the light of the oncology framework, we conducted a literature review on measures used to assess delayed recall impairment due to medial temporal lobe dysfunction (i.e., free and cued word list recall tests). Ample evidence is available for phases 1 (rationale for use), 2 (discriminative ability), and 3 (early detection ability) for many of the tests in routine use. Evidence about phase 4 (performance in real world) and phase 5 (quantify impact and costs) is yet to come. Administration procedures have been standardized and cutoff scores are well validated in large Alzheimer's disease and mild cognitive impaired series. Some aspects (e.g., different task formats), however, hamper the comparability of results among different populations and the reproducibility between laboratories. No definite guideline for their use can thus be proposed at the moment. Accordingly, the maturity of such markers is not yet sufficient and requires future investigation to promote the proper use of memory measures in clinical settings.

Mots-clé
Alzheimer Disease/diagnosis, Alzheimer Disease/physiopathology, Alzheimer Disease/psychology, Biomarkers/analysis, Cognitive Dysfunction/diagnosis, Cognitive Dysfunction/psychology, Cues, Early Diagnosis, Humans, Memory, Episodic, Mental Recall, Neuropsychological Tests, Reproducibility of Results, Temporal Lobe/physiopathology, 5-Phases, Alzheimer's disease, Biomarker development, Biomarker-based diagnosis, Cued recall tasks, Delayed recall, Early diagnosis, Episodic memory, Free word list tests, Mild cognitive impairment
Pubmed
Web of science
Création de la notice
28/03/2017 18:14
Dernière modification de la notice
20/08/2019 15:25
Données d'usage